

PC19184 (AG0184)

Information Disclosure Statement For Appln. No. 10/631,358



certificate of Mailing (37 C.F.R. §1.8);

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 26th day of August, 2003.

s/ Janice Alcafaras
Janice Alcafaras

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
DAVID JOHN KUCERA, ET AL.

Serial No.: 10/631,358

Filed: July 30, 2003

For: PROCESS AND CHIRAL AMINE
INTERMEDIATES USEFUL FOR
PREPARATION OF ANTIPROLIFERATIVE 2,
4-DIAMINOTHIAZOLE AMIDE COMPOUNDS

Group Art Unit: TBA

Examiner: TBA

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the art documents listed on the attached Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.


This Information Disclosure Statement is being filed within the period specified at 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached Form PTO-1449 and returning a copy of the initialed form to Applicant.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified at 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.


Respectfully submitted,

Date: August 26, 2003



Wendy Lei Hsu
Attorney For Applicants
Registration No. 42,794

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4652
Fax: (858) 678-8233



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICATION**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/631,358
Filing Date	July 30, 2003
First Named Inventor	David Kucera
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC19184 (AG0184)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			
	AA	2002/0025976	02-28-2002	Agouron Pharmaceuticals, Inc.	
	AB	6,114,365	09-05-2000	Pharmacia & Upjohn S.P.A.	
	AC	6,262,096	07-17-2001	Bristol-Myers Squibb Company	
		10/190,219	N/A	Agouron Pharmaceuticals, Inc.	
		60/402,408	N/A	Agouron Pharmaceuticals, Inc.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AD	WO 00/17175 ✓	03-30-2000	Vertex Pharmaceuticals Incorporated		
	AE	WO 00/26202 ✓	05-11-2000	Pharmacia & Upjohn S.P.A.		
	AF	WO 00/26203 ✓	05-11-2000	Pharmacia & Upjohn S.P.A.		
	AG	WO 00/75120	12-14-2000	Agouron Pharmaceuticals, Inc.		
	AH	WO 01/44241	06-21-2001	Bristol-Myers Squibb Co.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICATION**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/631,358
Filing Date	July 30, 2003
First Named Inventor	David Kucera
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC19184 (AG0184)

AI	WO 01/44242	06-21-2001	Bristol-Myers Squibb Co.		
AJ	WO 99/21845	05-06-1999	Agouron Pharmaceuticals, Inc.		
AK	WO 99/24035	05-20-1999	Bristol-Myers Squibb Co.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AL	BAER, et al., "A Novel Solid-Phase Approach to 2,4-Diaminotiazoles" <i>J. Comb. Chem.</i> , 2001, pages 16-19, vol. 3.	
	AM	BINU, et al., "Synthesis and Cyclization of 1-(N-Nitroamidino)Thioureas to 2,4-Diaminotiazoles" <i>Org. Prep. Proced. Intl.</i> , 1998, pages 93-96, vol. 30.	
	AN	DEVI, et al., "Synthesis of 2, 4-Diamino-5-(FUR-2-OYL), (THIEN-2-OYL), and (PYRID-2-OYL) Thiazoles" <i>Syn. Comm.</i> , 2002, pages 1523-1528, vol. 32.	
	AO	FISHBEIN, et al., "Treatment of Restenosis by Controlled-Release Delivery System of Tyrphostins" <i>Drug Dev. Res.</i> , 2000, pages 487-496, vol. 50.	
	AP	GARCIA-ECHEVERRIA, et al., "ATP Site-Directed Competitive and Irreversible Inhibitors of Protein Kinases" <i>Med. Res. Rev.</i> , 1999, pages 28-57, vol. 20.	
	AQ	GEWALD, et al., "4-Amino-thiazole" <i>J. Prakt. Chem.</i> , 1967, pages 97-104, vol. 35.	
	AR	GRAY, et al., "ATP-Site Directed Inhibitors of Cyclin-dependent Kinases" <i>Curr. Med. Chem.</i> , 1999, pages 859-875, vol. 6.	
	AS	GRUDZINSKI, et al., "Synteza Pochodnych 1, 2-Dwuaminopropanu I. Otrzymywanie D, L-1-Dwumetyloamino-2-Aminopropanu" <i>Acta Pol. Pharm.</i> , 1976, pages 571-576, vol. 33.	
	AT	GUTHRIE, et al., "Carbanions. Electron Transfer vs. Proton Capture. 7. Electron-Transfer Oxidation of an Amino Acid Derived Carbanion" <i>J. Org. Chem.</i> , 1981, pages 498-501, vol. 46.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICATION**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/631,358
Filing Date	July 30, 2003
First Named Inventor	David Kucera
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC19184 (AG0184)

AU	ISOGAI, et al., "Structure of a Peptidal Antibiotic P168 produced by Paecilomyces lilacinus (Thom) Samson" <i>J. Chem. Soc. Perkin Trans.</i> , 1984, pages 1405-1411, vol. 1.
AV	JENARDANAN, et al., "1-(N-Arylthiocarbamoyl) Amidino-3, 5-Dimethyl Pyrazoles – Preparation and Use in Heterocycle Synthesis" <i>Syn. Comm.</i> , 1997, pages 3457-3462, vol. 27.
AW	KAMINSKI, et al., "2-Chloro-4,6-Dimethoxy-1,3,5-Triazine. A New Coupling Reagent for Peptide Synthesis" <i>Synthesis</i> , 1987, pages 917-920, vol. 20.
AX	KUNISHIMA, et al., "4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium Chloride: An Efficient Condensing Agent Leading to the Formation of Amides and Esters" <i>Tetrahedron</i> , 1999, pages 13159-13170, vol. 55.
AY	LI, et al., "An Improved Procedure for the Preparation of Isothiocyanates from Primary Amines by Using Hydrogen Peroxide as the Dehydrosulfurization Reagent" <i>J. Org. Chem.</i> , 1997, pages 4539-4540, vol. 62.
AZ	MASQUELIN, et al., "A New General Three Component Solution-Phase Synthesis of 2-Amino-1, 3-Thiazole and 2,4-Diamino-1,3-Thiazole Combinatorial Libraries" <i>Tetrahedron</i> , 2001, pages 153-156, vol. 57.
BA	NGUYEN, et al., "7SK Small Nuclear RNA Binds to and Inhibits the Activity of CDK9/Cyclin T Complexes" <i>Nature (London)</i> , 2001, pages 322-325, vol. 414.
BB	PATANI, et al., "Bioisosterism: A Rational Approach in Drug Design" <i>Chem. Rev.</i> , 1996, pages 3147-3176, vol. 96.
BC	RAJASEKHARAN, et al., "Studies on the Synthesis of 5-Acyl-2,4-Diaminothiazoles From Amidinothioureas" <i>Synthesis</i> , 1986, pages, 353-355.
BD	RAO, et al., "Cyclin-Dependent Kinases and Their Small-Molecule Inhibitors in Cancer Therapy", <i>Targets Cancer Chemothe.</i> , 2002, pages 145-178.
BE	SCHANG, et al., "Roscovitine, a Specific Inhibitor of Cellular Cyclin-Dependent Kinases, Inhibits Herpes Simplex Virus DNA Synthesis in the Presence of Viral Early Proteins" <i>J. Virol.</i> , 2000, pages 2107-2120, vol. 74.
BF	STILL, et al., "Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution" <i>J. Org. Chem.</i> , 1978, page 2923, vol. 43.
BG	TANIGUCHI, et al., "Induction of the p16 ^{INK4a} Senescence Gene as a New Therapeutic Strategy for the Treatment of Rheumatoid Arthritis" <i>Nat. Med.</i> , 1999, pages 760-767, vol. 5.
BH	TOLDEDO, et al., "The Structure-Based Design of ATP-Site Directed Protein Kinase Inhibitors" <i>Curr. Med. Chem.</i> , 1999, pages 775-805, vol. 6.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/631,358
Filing Date	July 30, 2003
First Named Inventor	David Kucera
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC19184 (AG0184)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICATION**
(Use as many sheets as necessary)

	BI	YANG, et al., "The 7SK Small Nuclear RNA Inhibits the CDK9/Cyclin T1 Kinase to Control Transcription" <i>Nature (London)</i> , 2001, pages 317-322, vol. 414.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See *Kinds Codes of USPTO Patent Documents* at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.